STOCK TITAN
  1. Home
  2. News
  3. DGX

Quest Diagnostics, Inc. - DGX STOCK NEWS

Welcome to our dedicated news page for Quest Diagnostics (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.

News
Universal DX Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
Rhea-AI Summary
UDX (Universal DX) announces a strategic collaboration with Quest Diagnostics (DGX) and the initial closing of its series B financing of approximately $70 million. The collaboration aims to improve colorectal cancer screening in the United States by combining UDX's Signal-C® technology with Quest's expertise and national scale. The company plans to pursue FDA premarket approval for its colorectal cancer screening blood test and enroll patients in a 15,000-patient study. The test has shown 93% sensitivity for colorectal cancer detection and 54% sensitivity for detection of precancerous lesions at 92% specificity overall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
News
Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) has been awarded a multi-year contract by the CDC to assess the burden of hepatitis C virus (HCV) in the United States. The company will provide research consulting, laboratory testing, and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
News
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index for Seventh Consecutive Year
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) receives a 100% score on the Corporate Equality Index for the seventh consecutive year, showcasing its commitment to LGBTQ+ workplace equality. The company has 10 Employee Business Networks, including the Pride EBN, which has been promoting awareness, education, and advocacy for the LGBTQ+ community for over 20 years. The Inclusion and Diversity Council advises senior leaders on I&D goals and priorities, representing the needs and perspectives of diverse demographics across the company and communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
none
News
ISO Standardization & Climate Action at Quest Diagnostics
Rhea-AI Summary
Quest Diagnostics (DGX) aims to expand its electric vehicle pilot project, secure ISO 14001 certification for additional lab locations, and transition 50% of its vehicle fleet to electric or hybrid engines by 2026. The company also achieved ISO 14001 certification for its esoteric laboratory facility in 2022 and is actively working on climate action, energy efficiency, and renewable energy procurement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
News
Quest Volunteers Bring Treats, No Tricks, to Ronald McDonald House New York
Rhea-AI Summary
Quest Diagnostics (DGX) Volunteers Bring Treats, No Tricks to Ronald McDonald House New York
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
News
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Rhea-AI Summary
Quest Diagnostics (DGX) and Scipher Medicine announced a collaboration to expand patient access to diagnostic services for rheumatoid arthritis (RA). Quest will provide RNA extraction and sequencing services for Scipher's PrismRA test, aiming to predict patient response to TNF inhibitor therapy. This partnership aims to improve patient outcomes and reduce healthcare costs for RA treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
News
Community Engagement at Quest Diagnostics
Rhea-AI Summary
Quest Diagnostics (DGX) Corporate Responsibility Report 2022: $15 million in corporate giving, 750,000 donated or discounted test requisitions, and $300,000 in matched employee donations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
News
Quest Diagnostics Approach to Patient- and Consumer-Centered Care
Rhea-AI Summary
Quest Diagnostics (DGX) aims to deliver empathetic, high-quality, and convenient individualized care. In 2022, the company strengthened its approach to patient-centered care through development programs and technology enhancements. This included new staff training and development programs, content and training through Everyday Excellence and Everyday Equity programs, collaboration with The Arnold P. Gold Foundation to train frontline employees in humanistic patient engagement, adoption of Franklin Covey's Speed of Trust® Program, and enhancing the patient experience using technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
-
News
Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
Rhea-AI Summary
UDX - Universal DX Announces Strategic Collaboration with Quest Diagnostics and $70 Million Series B Financing for Colorectal Cancer Screening Blood Test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
News
Supply Chain Management at Quest Diagnostics
Rhea-AI Summary
Quest Diagnostics: Emphasizing Supplier Code of Conduct and ESG Screening in Supply Chain Management. The PR discusses Quest Diagnostics' commitment to ethical, safe, and high-quality services through its Supplier Code of Conduct. It also highlights the integration of ESG screening factors into its strategic sourcing process and the successful rollout of ESG assessments to over 40% of suppliers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
Stock DGX logo
Quest Diagnostics, Inc.

NYSE:DGX

DGX Rankings

#614 Ranked by Market Cap
#2771 Ranked by Stock Gains
#1358 Ranked by Dividends

DGX Stock Data

14.27B
109.71M
0.43%
91.73%
2.29%
Medical Laboratories
Health Care and Social Assistance
Link
US
Secaucus

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator